Saturday 17 October 2026
Export BVS’s income statement to Excel — free account
Bioventus Inc.
BVS Healthcare Medical Devices
Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
13.30
0.51
−3.69%
Follow BVS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
21.92 | 21.92 | 21.92 | 21.92 | 21.92 | 32.43 | 0.00 | 0.00 | 0.00 | 21.88 |
Piotroski F-Score |
— | — | — | — | — | 4 | 2 | 4 | 5 | 8 |
Altman Z-Score |
— | — | — | — | — | 1.03 | (0.12) | 0.22 | 0.89 | 1.26 |
P/S ratio |
0.29 | 0.29 | 0.29 | 0.29 | 0.29 | 1.53 | 0.31 | 0.64 | 1.18 | 0.87 |
Altman Z″-Score (non-manufacturers) |
— | — | — | 1.24 | 0.95 | 1.30 | (0.91) | (0.83) | (0.79) | 0.54 |
P/FCF ratio |
1.39 | 1.39 | 1.39 | 1.39 | 1.39 | 69.57 | 0.00 | 41.21 | 17.94 | 6.87 |
P/Operating CF |
3.70 | 3.70 | 3.70 | 3.70 | 3.70 | 50.23 | 30.55 | 31.70 | 35.08 | 13.06 |
Beneish M-Score |
— | — | — | — | (3.01) | (1.86) | (2.87) | (3.52) | (3.08) | (2.77) |
P/B ratio |
0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 1.23 | 0.39 | 1.49 | 3.65 | 2.17 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.61 | 0.61 | 0.61 | 0.61 | 0.61 | 2.25 | 1.07 | 1.34 | 1.70 | 1.30 |
EV/EBITDA |
3.88 | 3.88 | 3.88 | 3.88 | 3.88 | 20.61 | 0.00 | 0.00 | 28.28 | 7.31 |
EV/Operating CF |
2.73 | 2.73 | 2.73 | 2.73 | 2.73 | 42.08 | (40.49) | 44.76 | 25.05 | 9.89 |
EV/FCF |
2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 102.14 | (36.50) | 86.04 | 25.72 | 10.24 |
Quick Ratio |
— | — | 1.78 | 1.68 | 1.43 | 0.96 | 0.55 | 0.91 | 0.80 | 1.12 |
Current Ratio |
— | — | 2.28 | 2.06 | 1.73 | 1.45 | 0.90 | 1.53 | 1.31 | 1.70 |
Net Debt/EBITDA |
0.00 | 0.00 | 2.69 | 2.17 | 2.04 | 6.57 | (3.47) | (14.69) | 8.56 | 2.40 |
Debt/Assets |
— | 0.00% | 0.00% | 41.91% | 38.10% | 29.18% | 30.46% | 48.69% | 46.11% | 43.00% |
Debt/Equity |
— | 0.00 | 0.00 | 1.36 | 1.31 | 0.67 | 1.01 | 1.79 | 1.81 | 1.29 |
Asset Turnover |
0.00 | 1.44 | 0.00 | 1.44 | 0.66 | 0.50 | 0.39 | 0.47 | 0.75 | 0.80 |
Operating CF/Net income |
(1.59) | 0.00 | (2.51) | 5.94 | 4.38 | 1.19 | 0.09 | (0.10) | (1.07) | 3.28 |
Capex/Depreciation |
— | 0.00 | (0.08) | (0.08) | (0.58) | (0.39) | (0.03) | (0.13) | (0.02) | (0.05) |
Interest Coverage |
1.87 | 1.33 | 1.33 | 1.45 | 2.18 | 10.85 | (13.91) | (2.01) | (0.39) | 2.04 |
| 0.00% | 0.00% | (12.49%) | 4.71% | 11.33% | 5.72% | (33.55%) | (49.34%) | (17.76%) | 10.98% | |
| 0.00% | (8.12%) | 0.00% | 2.90% | 3.39% | 2.25% | (12.21%) | (14.31%) | (4.70%) | 3.22% | |
ROIC |
— | 0.00% | 10.49% | 6.99% | 5.40% | 0.89% | (13.06%) | (8.82%) | (1.98%) | 7.16% |
Return on Tangible Assets |
0.00% | 0.00% | (20.44%) | 6.95% | 17.08% | 18.41% | 3,981.54% | (121.01%) | (39.17%) | 16.92% |
Average Days of Receivables |
0.00 | 0.00 | 83.48 | 91.35 | 100.33 | 105.85 | 97.14 | 87.48 | 81.11 | 82.44 |
Research and Development Expense of Revenue |
2.88% | 2.54% | 2.54% | 3.25% | 3.49% | 4.42% | 4.66% | 2.62% | 2.43% | 2.13% |
Selling, General and Administrative Expense of Revenue |
58.40% | 60.05% | 60.05% | 58.35% | 60.12% | 59.01% | 64.86% | 59.31% | 59.97% | 55.28% |
Intangible Assets out of Total Assets |
— | 0.00 | 0.00 | 0.56 | 0.49 | 0.69 | 0.47 | 0.60 | 0.57 | 0.55 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4.61% | 3.43% | 0.53% | 2.32% | 2.23% |
Graham Net Nets |
(1.47) | (1.47) | (1.47) | (1.47) | (1.47) | (0.65) | (4.29) | (0.98) | (0.39) | (0.37) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 24.09 | 10.86 | 0.00 | 0.00 | 0.00 | 5.12 |
Earnings Yield |
4.56% | 4.56% | 4.56% | 4.56% | 4.56% | 3.08% | (98.85%) | (48.00%) | (4.86%) | 4.57% |
Free Cash Flow Yield |
71.93% | 71.93% | 71.93% | 71.93% | 71.93% | 1.44% | (9.37%) | 2.43% | 5.58% | 14.55% |
Revenue per Share |
4.83 | 65.14 | 65.14 | 5.99 | 5.65 | 9.48 | 8.34 | 8.18 | 8.88 | 8.53 |
Operating CF per Share |
0.65 | 0.00 | 9.22 | 0.72 | 1.26 | 0.51 | (0.22) | 0.24 | 0.60 | 1.12 |
Capex per Share |
0.00 | 0.00 | (0.52) | (0.04) | (0.29) | (0.30) | (0.02) | (0.12) | (0.02) | (0.04) |
Free Cash Flow per Share |
0.65 | 0.00 | 8.70 | 0.68 | 0.97 | 0.21 | (0.24) | 0.13 | 0.59 | 1.08 |
Cash per Share |
0.00 | 0.00 | 8.78 | 1.14 | 1.53 | 1.08 | 0.49 | 0.59 | 0.64 | 0.77 |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 2.56 | 2.54 | 11.74 | 6.71 | 3.53 | 2.88 | 3.43 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.00 | 0.00 | 2.56 | 2.54 | 11.74 | 6.71 | 3.53 | 2.88 | 3.43 |
Free Cash Flow |
37.15 | 0.00 | 42.63 | 38.37 | 55.22 | 9.47 | (15.01) | 7.98 | 37.79 | 72.11 |
Working Capital |
— | — | 83.00 | 94.02 | 89.21 | 82.24 | (31.44) | 92.50 | 65.21 | 112.46 |
Capital Expenditures |
— | 0.00 | (2.56) | (2.34) | (16.58) | (13.52) | (1.48) | (7.36) | (1.01) | (2.56) |
Net Current Asset Value |
— | 0.00 | 148.00 | (143.76) | (138.51) | (428.97) | (687.85) | (321.79) | (266.74) | (182.27) |
EV/EBIT |
9.21 | 9.21 | 9.21 | 9.21 | 9.21 | 80.21 | 0.00 | 0.00 | 0.00 | 13.68 |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | 0.05 | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 |
Price to Operating Income |
4.43 | 4.43 | 4.43 | 4.43 | 4.43 | 54.63 | 0.00 | 0.00 | 0.00 | 9.18 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | 0.00 | 6.18 | 6.75 | 4.16 | 1.52 | 2.02 | 1.57 | 1.83 | 2.15 |
Cash ROIC |
0.00% | 0.00% | 17.91% | 9.40% | 13.17% | 1.01% | (1.74%) | 1.22% | 6.71% | 12.57% |
Accounts Receivable Turnover |
0.00 | 0.00 | 4.04 | 4.30 | 3.70 | 4.04 | 3.92 | 3.96 | 4.58 | 4.44 |
Accounts Payable Turnover |
0.00 | 0.00 | 12.02 | 12.59 | 16.14 | 12.02 | 6.75 | 6.17 | 7.92 | 10.40 |
Inventory Turnover |
0.00 | 0.00 | 3.12 | 3.35 | 3.11 | 2.82 | 2.47 | 2.09 | 2.01 | 2.06 |
Average Days of Payables |
0.00 | 0.00 | 34.69 | 25.85 | 18.42 | 48.16 | 73.99 | 45.66 | 46.73 | 22.17 |
Days of Inventory on Hand |
0.00 | 0.00 | 117.09 | 109.68 | 121.28 | 175.64 | 170.90 | 181.03 | 182.40 | 166.82 |
Average Receivables |
— | — | 79.00 | 79.06 | 86.71 | 106.62 | 130.63 | 129.54 | 125.09 | 127.85 |
Average Payables |
— | — | 7.00 | 7.22 | 5.43 | 10.67 | 26.81 | 29.87 | 23.36 | 17.31 |
Average Inventory |
— | — | 27.00 | 27.16 | 28.22 | 45.40 | 73.23 | 88.05 | 91.90 | 87.36 |
Average Assets |
— | 221.50 | 0.00 | 236.20 | 483.44 | 860.16 | 1,299.26 | 1,091.78 | 769.43 | 705.76 |
Average Common Equity |
— | — | 144.00 | 145.31 | 144.89 | 338.97 | 473.01 | 316.67 | 203.36 | 207.03 |
Columns are period end dates